leisure time -WSS

leisure time

author：knowledge 2025-09-27 21:27:32 - browse：89

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout LOUD podcast: Live from the 2023 STAT Summit

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: The economic case for universal basic health care

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

CZI to create biohub to build anti

Results on Novartis prostate cancer therapy could expand its use

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Asbestos ban is immediate, but health effects will linger for decades

Duchenne breakthrough therapy leaves behind pioneering families

STAT Readout Newsletter: Biotech news today

Hepatitis C has a cure — but many Americans still lack access to it

CRISPR technology availability, affordability needs to be expanded

How to save PrEP access — and even expand it

Steward Health Care expansion into Malta flopped

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

CRISPR technology availability, affordability needs to be expanded

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

CZI to create biohub to build anti

Chinese researcher claims birth of first gene

Medical devices makers are asking for forgiveness, not permission

focus

explore

knowledge

hotspot